Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Study sponsor: Iovance Biotherapeutics, Inc. · IOVA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-03-01Estimated
Enrollment · participants670Estimated
Source updated2026-09-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.